Objectives: Quite a number of patients diagnosed with major depression are resistant to several well carried-out psychopharmacological interventions. It remains unclear as to how the serotonergic system is implicated in the phenomenon of treatment-resistance. regulated. However, whether this assumed underlying pathophysiological mechanism is due solely to abnormalities in the serotonergic system remains to be answered.
Introduction
Major depression is a worldwide mental health problem affecting millions (Nemeroff 2007a ).
Unfortunately, not all depressed patients respond to the available pharmacological treatment algorithms and refractory depression is not uncommon (Fava 2003) . It is estimated that treatment-resistance occurs in up to 40% of depressive episodes that are adequately treated with first-line antidepressant therapy (Souery et al. 2007 ). Ten percent or even more of patients suffering from major depression are resistant to several psychopharmacological interventions, even when adhering to treatment guidelines (Fagiolini & Kupfer 2003; Berlim & Turecki 2007) . Not surprisingly, it has been proposed that severe treatment resistance could be a different type of depression (Nemeroff 2007b) . Furthermore, when challenged with clinical nonresponse, treatment options are limited (Shelton et al. 2010; Ward & Irazoqui 2010) .
The serotonergic system remains one of the main targets of psychotropic drug intervention to treat depression (Neumeister & Charney 2002) . Ascending serotonergic projections arise primarily from the raphe nuclei in the brainstem and 'arborize' widely throughout cortico-subcortical structures, innervating forebrain and limbic areas (Hensler 2006) . Prefrontal cortical serotonergic innervations have been found to be reduced in depressed individuals (Larisch et al. 2001; Arango et al. 2002) . Being part of the G-protein coupled 5-HT 2 serotonin receptor family, post-synaptic 5-HT 2A receptors are implicated in the pathophysiology of many neuropsychiatric disorders including major depression, and they are implicated in several brain functions such as appetite control, thermoregulation, emotion, personality, cognition, ageing and sleep (Aghajanian & Sander-Bush 2002; Celada et al. 2004; Frokjaer et al. 2010) . These receptors have widespread distributions throughout the cortex, with high densities in the frontal cortex (Barnes & Sharp 1999) . However, it has to be noted that discrepant results in 5-HT 2A receptor research in depression have been reported, with some authors demonstrating 5-HT 2A receptor increases, others demonstrating decreases, or no differences in receptor ligand binding at all (D'haenen 2004; Bhagwagar et al. 2006) . Confounding variables such as sample size, heterogeneity, age, antidepressant drug status and suicide levels could be an explanation for these observed discrepancies. Nevertheless, there seems to be a growing consensus 
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Few studies have examined the differences in 5-HT 2A receptor binding between currently depressed antidepressant naïve (ADN) patients, depressed patients who have been treated with antidepressants, and never-depressed healthy controls (Massau et al. 1997; Messa et al. 2003; Schins et al. 2005) . Although negative results are also reported (Schins et al. 2005) , Messa et al (2003) found decreased frontal cortical 5-HT 2A binding indices in symptomatic ADN patients as compared to their control group.
They suggested that 5-HT 2A receptors are reduced in depressive patients during symptomatic periods.
However, at this point it is not clear whether these serotonergic abnormalities found in unipolar depressed samples are any different when encountered with treatment resistance. No studies examined the possible differences at the level of 5-HT 2A receptor BI between untreated depressed patients and AD-free depressed patients who were "unsuccessfully" treated with several psychopharmacological interventions.
In the present study, we focused on the 5-HT 2A receptors in well defined gender-controlled homogeneous groups of unipolar depressed patients, using SPECT and the radioligand 4-amino-N-[1-[3-(4-fluorophenoxy)propyl]-4-methyl-4-piperidinyl]-5-iodo-2-methoxybenzamide ( 123 I-5-I-R91150) (Terriere et al. 1995) . As age-dependent reductions in 5-HT 2A receptor binding indices in the cortex have consistently been reported (Baeken et al. 1998; Meltzer et al. 1998) , patients and controls were also matched for age.
Because hormonal processes seem to differ between depression subtypes (Porter & Gallagher 2006) , our patient group consisted only of depressed patients with melancholic features. Melancholic depression is characterized by anhedonia, i.e., distinct quality of depressed mood, depression symptoms worse in the mornings, early morning awakenings, psychomotor retardation, weight loss, and excessive feelings of guilt (Gold & Chrousos 2002) . Treatment-resistant depressed (TRD) patients had had a minimum of two unsuccessful treatment trials with serotonin reuptake inhibitors/ noradrenaline and serotonin reuptake inhibitors (SSRI/NSRI) and one failed clinical trial with a tricyclic antidepressant (TCA). TRD patients were tapered-off their psychotropic drugs, and all were at least medication-free for at least two weeks before SPECT scanning. Only when necessary TRD patients were kept on a steady dose of benzodiazepines.
Firstly, in line with former research, we hypothesized that compared to never depressedindividuals in both the currently depressed ADN patients and the treatment-resistant depressed (TRD) 
Subjects
The study was approved by the ethics committee of the University Hospital (UZBrussel) and all subjects gave written informed consent. As the focus of this research is treatment resistance, fifteen righthanded unipolar melancholic TRD patients (Female:Male (F:M)= 9:6; age= 38.6±9.5y) were studied. See also Table 1 . They were closely matched with fifteen first episode right-handed medication-free unipolar melancholic ADN depressed patients (F:M= 9:6; age= 36.3±9.8y) and fifteen never-depressed medicationfree healthy volunteers (F:M= 9:6; age= 37.01± 9.8y), who were included as control group. In other words, for each female or male TRD patient a suitable female or male ADN patient and healthy control was selected, matched for age as close as possible. Parts of the TRD patient and the control SPECT data were also used for another study, examining the treatment effects of high frequency repetitive transcranial magnetic stimulation in these kinds of patients (Baeken et al. 2011 Patients with substance abuse/dependence were not included in the study. Because in post-mortem studies increased 5-HT 2(A) receptor BI are reported in the frontal cortices of suicide victims , suicidal attempts during the current depressive episode were considered as an exclusion criterion.
All participants were in good physical health. Severity of depression was assessed with the 17-item
Hamilton Depression scale (HDRS; Hamilton 1967) by a qualified psychiatrist, unrelated to the study. All ADN patients were by definition drug-free in the current episode, but they were also never treated with antidepressants in the past. All TRD patients were considered at least stage III treatment resistant as described by Rush et al (2003) : they had had a minimum of two unsuccessful treatment trials with an SSRI/NSRI and one failed clinical trial with a TCA. All unsuccessful treatment trials were carried-out at therapeutic antidepressant dosages for at least eight weeks. After a washout period, all TRD patients were free from antidepressants, neuroleptics and mood stabilizers for at least two weeks. This AD-free time frame is commonly used in PET/SPECT brain imaging studies examining serotonin receptors (D'haenen et 7 al., 1992; Parsey et al., 2006) . All TRD patients were closely monitored by their personal physicians during the washout of their current psychopharmacological treatments. In agreement with the treating physician, when necessary TRD patients were kept on a steady dose of benzodiazepines (n=6).
Scanning Procedure
All patients received a static baseline SPECT scan. SPECT-imaging was performed with a
Siemens MultiSPECT triple-headed gamma camera, equipped with parallel-hole medium-energy collimators. All subjects received oral Lugol's solution containing 400mg of potassium iodide 15 min prior to injection for thyroid blockage. An average of 150MBq 123 I-5-I-R91150, was manually injected. SPECT acquisition was performed at a minimum of 120 min after administration of the tracer. Data were collected from 96 angular positions over 360° in a 128x128 matrix, with a total acquisition time of 32 min.
Reconstruction of the acquired projection images was performed using an iterative reconstruction algorithm (Ordered Subset Expectation Maximization, OSEM, 8 iterations, 8 subsets) and filtered with a 3D Gaussian using 15mm full-width at half-maximum.
SPECT scans were automatically co-registered to a template image that was placed in a predefined stereotactic (image) space (BRASS; Nuclear Diagnostics Ltd., Sweden). For a more detailed description of the methods for co-registration of SPECT receptor data using transmission images, the reader is referred to the paper of Van Laere and colleagues (2001) . The sequential acquisition of transmission and emission images can be used to anatomically standardize the emission image using the same linear parameters as those used for the transmission image . The latter is first reoriented to a template in Talairach space and the same transformation is then given to the emission images. On the Talairach templates, a predefined volume-of-interest (VOI) set can be constructed (originally performed on perfusion SPECT images), which allows a user-independent sampling of the whole brain volume of different individuals without previously available structural information. All images were visually double-checked to ensure correct anatomical positioning of the predefined VOIs (Goethals et al. 2004 ).
Radioactivity estimates in the cortex were assumed to represent total ligand binding (specific plus nonspecific binding plus free ligand) (Goethals et al. 2004) . Because very few 5-HT 2A receptors are present in the cerebellum, this region was chosen to represent nonspecific activity (Terriere et al. 1995) .
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Calculation of relative indices of specific BI was performed by VOI normalization to the activity per volume element in the cerebellum. Under these pseudo-equilibrium circumstances, BI is directly related to the in vivo receptor density (B max ) and affinity (K d ). BI was defined as (target activity-background activity in the brain)/(background activity) which was operationally estimated as (counts/pixel in VOI-counts/pixel in the cerebellum)/(counts/pixel in the cerebellum) .
Four bilateral cortical VOIs were defined and selected: the frontal cortex (FC), the temporal cortex 
Statistical Methods
All statistical analyses were performed with SPSS 15 (Statistical Package for the Social Sciences).
Significance threshold was set at a two-tailed probability of p<.05 for all analyses.
To compare group 5-HT 2A receptor BI including the four cortical VOIs, in a first set of analyses the 5-HT 2A receptor uptake values were analyzed as multiple dependent variables in a MANCOVA analysis with the four regions (VOI) as the dependent variables, group (ADN versus TRD patients versus neverdepressed controls) as the fixed between subjects factor, and age as covariate. For the univariate follow-up analyses of the omnibus MAN(C)OVA analyses we used Bonferroni corrected p-values for 4 comparisons.
All further post hoc analyses were also Bonferroni corrected.
In a second set of analyses, to compare group 5-HT 2A receptor BI in the frontal cortex, these analyses were repeated with the four frontal VOIs.
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In a last set of analyses confined to the TRD patients, we evaluated whether illness duration, SSRI/TCA last treatment before washout could influence 5-HT 2A receptor BI patterns. These analyses were separately performed for the whole brain cortical VOIs and the frontal VOIs.
Results

Group results.
See Table 2 for an overview of the 5-HT 2A receptor BI for the different groups.
Mean HDRS scores for ADN depressed patients were 22.4±6.8 and 26.5±3.3 for TRD patients, indicating moderate to severe depression. Independent t-tests showed no significant differences in depression severity (t(28)=1.81, ns). A one-way ANOVA, with age as the dependent variable and group as the fixed factor, did not show significant group differences in age.
Whole brain.
The MANCOVA analysis, with the different cortical VOIs (FC, TC, PC, OC) as dependent variables, group (ADN versus TRD patients versus never-depressed controls) as the between group fixed factor, and age as covariate, showed that there were no significant effects implying the covariate age.
Further, no significant group by region interaction effect was found. receptor BI between these two groups (t(13)= .71, ns). Age (t(13)=.02, ns), depression severity (t(13)=.24, ns) and gender (χ 2 (1, n= 15) = .60, ns) were also not different between these two groups. Furthermore, we evaluated whether benzodiazepine treatment interfered with our measurements. Independent t-test showed no differences between those TRD patients under benzodiazepine treatment (n= 6) and those without 12 benzodiazepines (n= 9) in FC 5-HT 2A receptor BI (t(13)=.45, ns), age (t(13)=.11, ns) or gender (χ 2 (1, n= 15) 2.27, ns). Because of the small sample size, we also applied non-parametric Mann-Whitney U tests to evaluate the influence of TCA treatment on 5-HT 2A receptor BI measurements. Again no significant group differences were observed for the FC. Mann-Whitney U tests also did not reveal significant benzodiazepine influences in FC 5-HT 2A receptor BI.
Frontal cortex.
To evaluate whether illness duration of their current depressive episode might influence 5-HT 2A
receptor BI measurements in the frontal cortex, we performed a MANCOVA analysis, with the four different frontal cortical VOIs as the dependent variables and duration of illness (in years) as covariate.
This analysis again showed no significant contribution of the covariate illness duration.
To verify whether the last medication before washout might have influenced 5-HT 2A receptor BI measurements, again we compared TRD patients with TCA washout (n=8) and patients without TCA washout (n=7). Independent t-tests showed no significant differences in 5-HT 2A receptor BI between these two groups for the DPFC (t(13)=1.10, ns) nor for the ACC (t(13)=.97, ns). To examine whether the use of benzodiazepines could have been a confounding factor, independent t-tests did not demonstrate 5-HT 2A receptor BI differences for the DPFC (t(13)=1.25, ns) nor for the ACC (t(13)=.85, ns). We also applied the non-parametric Mann-Whitney U tests to evaluate the influence of current TCA treatment on 5-HT 2A receptor BI measurements. No significant group differences were observed for the DPFC and the ACC.
Mann-Whitney U tests confirmed the lack of benzodiazepine confounds on 5-HT 2A receptor BI for the DPFC and the ACC. Concerning the results in our TRD patient group, one could argue that the observed 5-HT 2A receptor BI decreases in the frontal cortex in the TRD patient group are merely the result of long-term AD therapy (Van Oekelen et al. 2003) . Given that our first episode ADN individuals, with a similar subtype of depression, showed no differences in 5-HT 2A BI compared to healthy controls we cannot exclude the possibility that the differences between ADN and TRD group are due to treatment exposure rather than depression itself. However, Messa et al (2003) studied a group of antidepressant naive depressed patients (thus without treatment exposure) who had from 0 to 3 former depressive episodes and they also showed shown that successful treatment response with SSRI and electroconvulsive shock therapy (ECT) was associated with prefrontal 5-HT 2A receptor up-regulation (Massau et al. 1997; Burnet et al. 1999; Zanardi et al. 2001) . Another confounding factor could have been the use of benzodiazepines in the TRD patient group. However, our analyses did not suggest such a possible influence on 5-HT 2A receptor BI in the cortical areas examined. Indeed, not all studies demonstrated an impact of these psychotropic drugs (Leysen et al. 1987; Messa et al. 2003) , and if they did, instead of a down-regulation, an up-regulation of 5-HT 2A receptors could be expected (Zanardi et al. 2001; Akin et al. 2004 ). Since increased 5-HT 2(A) receptor BI has been reported post-mortem in the frontal cortices of suicide victims , it is also important to point-out that no suicide attempt had occurred in our sample at least 6 months prior to this study.
Our results could imply that the reduced cortical 5-HT 2A receptor binding found in melancholic TRD patients might be specific for the underlying pathophysiological state of the disease. This assumption is also in line with the prefrontal neurodegenerative effects due to hypercortisolaemia in long-term melancholically depressed states (Porter & Gallagher 2006) .
To further elucidate the impact of treatment resistance in melancholic depression, we further examined the 5-HT 2A receptor BI within these frontal cortical areas. Compared to controls and ADN patients, significant reductions in the DPFC and ACC 5-HT 2A receptor BI in TRD patients were observed.
Interestingly, other types of brain imaging studies, not all related to the serotonergic neurotransmitter system, reported on dysfunctional 'fronto-cingulate networks' frequently found in major depressive disorder (Mayberg 2003; Drevets et al. 2008; Pizzagalli 2011) . Besides prefrontal decreases in neuronal activity, decreased ACC activation patterns have frequently been documented (Davidson et al. 2002) . In major depression dorsal prefrontal-cingulate cortical abnormalities have been commonly observed, in particular during emotional processing and cognitive control (Drevets et al. 2008 ). These cognitive processes are in particular problematic for depressed patients (Mayberg 2003 would not be significantly present during a first depressive episode. However, as we did not integrate neurocognitive tasks in our design these assumptions must be interpreted cautiously.
Although our findings could suggest specific neurobiological abnormalities for treatment resistant melancholic depression, at this point these assumptions remain to some extent speculative as this study is limited by some methodological issues. Besides that the sample size is relatively small, the antidepressantfree period of two weeks after washout could be interpreted as relatively short, in spite that this extent of time is in range with other unipolar depressed patient studies examining 5-HT 2A receptors (D'haenen et al. 1992; Meyer et al. 1999; Van Oekelen et al. 2003) . Although the main goal of this study was to investigate treatment-resistance in melancholic depressed patients by examining the 5-HT 2A receptor BI, at this point we cannot predict who in the end of our ADN patients will be a stage III AD non-responder. Albeit statistically this should be around 10-15% of this group, this could have introduced some bias in our 5-HT 2A receptor BI measurements. However, the fact that we observed a significant difference between the TRD and the ADN patients despite that a part of the ADN group might reveal to be also treatment resistant is indicative of the magnitude of the effect.
In conclusion, our observations indicate that on the cortical level 5-HT 2A receptor binding indices do not significantly differ in first-episode melancholic depressed patients compared to healthy controls, at least indicating a limited short-term impact on the serotonergic system when first-time currently depressed. (*) significant different group effects at a two-tailed probability of p< .05. ADN= antidepressant naïve. TRD= treatment resistant depression. BI= Binding Index.
